Hikma Pharmaceuticals Plc’s (HIK) “Overweight” Rating Reaffirmed at JPMorgan Chase & Co.
Several other analysts have also recently weighed in on the company. Citigroup Inc. restated a neutral rating on shares of Hikma Pharmaceuticals Plc in a report on Wednesday. Morgan Stanley raised Hikma Pharmaceuticals Plc from an equal weight rating to an overweight rating and cut their price objective for the stock from GBX 2,500 ($31.23) to GBX 2,200 ($27.49) in a research note on Tuesday. HSBC cut their price objective on Hikma Pharmaceuticals Plc from GBX 1,985 ($24.80) to GBX 1,800 ($22.49) and set a hold rating on the stock in a research note on Friday, November 11th. Jefferies Group cut their price objective on Hikma Pharmaceuticals Plc from GBX 2,500 ($31.23) to GBX 2,000 ($24.99) and set a buy rating on the stock in a research note on Friday, November 11th. Finally, Numis Securities Ltd reaffirmed a buy rating and issued a GBX 2,350 ($29.36) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, November 10th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of GBX 2,337.40 ($29.20).
Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.36% during mid-day trading on Thursday, reaching GBX 1658.00. The company had a trading volume of 364,034 shares. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The firm’s market capitalization is GBX 3.75 billion. The firm’s 50-day moving average is GBX 1,869.22 and its 200-day moving average is GBX 2,194.52.
In other news, insider Al-Husry,Ali purchased 140,000 shares of the company’s stock in a transaction dated Wednesday, August 31st. The shares were purchased at an average price of GBX 2,150 ($26.86) per share, with a total value of £3,010,000 ($3,760,619.69). Also, insider Said Darwazah purchased 10,000 shares of the company’s stock in a transaction dated Wednesday, September 28th. The shares were purchased at an average cost of GBX 2,085 ($26.05) per share, for a total transaction of £208,500 ($260,494.75).
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.